% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Hemminki:289178,
      author       = {K. Hemminki$^*$ and F. Zitricky and K. Sundquist and J.
                      Sundquist and A. Försti$^*$ and A. Hemminki and O.
                      Hemminki},
      title        = {{C}ritical survival periods in prostate cancer in {S}weden
                      explored by conditional survival analysis.},
      journal      = {Cancer medicine},
      volume       = {13},
      number       = {7},
      issn         = {2045-7634},
      address      = {Hoboken, NJ},
      publisher    = {Wiley},
      reportid     = {DKFZ-2024-00613},
      pages        = {e7126},
      year         = {2024},
      note         = {#EA:Z999#},
      abstract     = {We wanted to characterize conditional survival in prostate
                      cancer (PC) in Sweden around and after 2005 when the vast
                      increase in incidence due to the opportunistic testing for
                      prostate specific antigen (PSA) culminated. We hypothesize
                      that analyzing survival data during that time period may
                      help interpret survival trends. We focus on stage-specific
                      analysis using conditional survival in order to define the
                      periods when deaths most commonly occurred.Data on PC
                      patients were obtained from the Swedish cancer registry for
                      analysis of 1-, 2.5- and 5-year relative survival and
                      conditional relative survival between years 2004 and 2018.
                      Tumor-node-metastatic stage classification at diagnosis was
                      used to specify survival.Small improvements were observed in
                      stage- and age-related relative survival duriring the study
                      period. Applying conditional relative survival showed that
                      survival in stage T3 up to 2.5 years was better than
                      survival between years 2.5 and 5. Survival in stage T4 was
                      approximately equal in the first and the subsequent 2.5-year
                      period. For M1, the first 2.5 year survival period was worse
                      than the subsequent one. The proportion of high risk and M1
                      disease in old patients (80+ years) remained very high and
                      their survival improved only modestly.The data indicate that
                      M1 metastases kill more patients in the first 2.5 years than
                      between years 2.5 and 5 after diagnosis; T4 deaths are equal
                      in the two periods, and in T3 mortality in the first
                      2.5-year period is lower than between years 2.5 and 5 after
                      diagnosis. Conditional survival could be applied to explore
                      critical survival periods even past 5 years after diagnoses
                      and to monitor success in novel diagnostic and treatment
                      practices. Improvement of survival in elderly patients may
                      require clinical input.},
      keywords     = {age (Other) / conditional relative survival (Other) /
                      prognosis (Other) / stage (Other) / treatment (Other)},
      cin          = {Z999 / B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)Z999-20160331 / I:(DE-He78)B062-20160331 /
                      I:(DE-He78)HD01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:38545829},
      doi          = {10.1002/cam4.7126},
      url          = {https://inrepo02.dkfz.de/record/289178},
}